Related Experiment Video
Updated: Jun 23, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Multi-omic analysis of dysregulated pathways in triple negative breast cancer
Fatima Sajjad1, Ahmer Jalal2, Amir Jalal3
1School of Interdisciplinary Engineering and Sciences, National University of Sciences and Technology (NUST), Islamabad, Pakistan.
Abstract:
The aggressive characteristics of triple-negative breast cancer (TNBC) and the absence of targeted medicines make TNBC a challenging clinical case. The molecular landscape of TNBC has been well-understood thanks to recent developments in multi-omic analysis, which have also revealed dysregulated pathways and possible treatment targets. This review summarizes the utilization of multi-omic approaches in elucidating TNBC's complex biology and therapeutic avenues. Dysregulated pathways including cell cycle progression, immunological modulation, and DNA damage response have been uncovered in TNBC by multi-omic investigations that integrate genomes, transcriptomics, proteomics, and metabolomics data. Methods like this pave the door for the discovery of new therapeutic targets, such as the EGFR, PARP, and mTOR pathways, which in turn direct the creation of more precise treatments. Recent developments in TNBC treatment strategies, including immunotherapy, PARP inhibitors, and antibody-drug conjugates, show promise in clinical trials. Emerging biomarkers like MUC1, YB-1, and immune-related markers offer insights into personalized treatment approaches and prognosis prediction. Despite the strengths of multi-omic analysis in offering a more comprehensive view and personalized treatment strategies, challenges exist. Large sample sizes and ensuring high-quality data remain crucial for reliable findings. Multi-omic analysis has revolutionized TNBC research, shedding light on dysregulated pathways, potential targets, and emerging biomarkers. Continued research efforts are imperative to translate these insights into improved outcomes for TNBC patients.
Insights
Multi-omic analysis reveals key pathways and targets in triple-negative breast cancer (TNBC), paving the way for personalized treatments. This approach enhances understanding of TNBC biology and guides the development of novel therapeutic strategies.
Area of Science:
- Oncology
- Genomics
- Proteomics
Background:
- Triple-negative breast cancer (TNBC) presents significant clinical challenges due to its aggressive nature and lack of targeted therapies.
- Recent advancements in multi-omic analysis have improved the understanding of TNBC's molecular complexity.
Purpose of the Study:
- To review the application of multi-omic approaches in understanding TNBC biology.
- To identify dysregulated pathways and potential therapeutic targets in TNBC.
Main Methods:
- Integration of multi-omic data, including genomics, transcriptomics, proteomics, and metabolomics.
- Analysis of dysregulated pathways such as cell cycle progression, immune modulation, and DNA damage response.
Main Results:
- Identification of potential therapeutic targets like EGFR, PARP, and mTOR pathways.
- Highlighting promising treatment strategies including immunotherapy, PARP inhibitors, and antibody-drug conjugates.
- Recognition of biomarkers (MUC1, YB-1, immune markers) for personalized treatment and prognosis.
Conclusions:
- Multi-omic analysis provides a comprehensive view of TNBC, enabling personalized treatment strategies.
- Challenges remain in data quality and sample size for robust findings.
- Continued research is essential to translate multi-omic insights into improved patient outcomes.
